bNAb sensitivity at screening for the placebo/placebo and lefitolimod/placebo groups.
bNAb sensitivity was primarily analyzed using the PhenoSense Monoclonal Antibody Assay with predefined IC90 thresholds for 3BNC117 ( < 1.5 µg/mL) and 10-1074 ( < 2.0 µg/mL) and maximum percentage inhibition (MPI) ≥ 98%. In seven participants, the PhenoSense Assay failed, and we secondarily used proviral HIV-1 envelope (
